<DOC>
	<DOCNO>NCT01215526</DOCNO>
	<brief_summary>Patients eligible hormone ablation therapy prescribe Firmagon follow maximum 3 year estimate progression free survival . Data testosteron level , QoL LUTS collect information available . Safety information ( adverse event ) collect .</brief_summary>
	<brief_title>A Study Into Effectivity Safety Firmagon , Prescribed Treatment Patients With Advanced Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Patients advance hormonedependent prostate carcinoma eligible hormone therapy Patients contraindication prescription FirmagonÂ®</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>